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ABSTRACT 
 
The antifungal polyene macrolide nystatin is produced by Streptomyces noursei ATCC 
11455. The nystatin biosynthesis gene cluster of Streptomyces noursei has been cloned and 
sequenced, and a biosynthesis route has been predicted. In the present work, investigation 
of genes presumably involved in post-PKS modifications of nystatin is described. The aim 
of this work was to better understand the nystatin biosynthesis and to further use this 
information for generation of novel nystatin analogues. Two PKS-modifications of the 
nystatin molecule were targeted in this study: glycosylation with mycosamine at C-19 and 
oxidation of the exocyclic methyl group at C-16. 
 
Two genes putatively involved in mycosamine biosynthesis (NysDIII and NysDII) and one 
in attachment of mycosamine to the nystatin aglycone (nysDI) have been identified in the 
nystatin gene cluster. Their functions have been suggested, respectively, as a putative 
mannose dehydratase, aminotransferase and a glycosyltransferase. The deoxysugar 
mycosamine is proposed to have an important function for the activity of nystatin. To better 
understand the biosynthesis and importance of mycosamine and to perform modifications 
of nystatin via this post-PKS modifying step, the mycosamine biosynthesis was studied. 
The NysDIII protein was overexpressed in Escherichia coli and purified, and its in vitro 
mannose 4,6-dehydratase activity was confirmed. To study the function of nysDII and 
nysDI, the genes were individually deleted from the S. noursei chromosome. Both mutants 
were shown to produce a mixture of nystatinolide and 10-deoxynystatinolide, albeit at 
considerably different levels. Complementation experiments unequivocally confirmed the 
involvement of these two in mycosamine biosynthesis and attachement. Both antifungal 
and hemolytic activity of the purified nystatinolides were tested, and were found to be 
strongly reduced compared to nystatin, confirming the importance of the mycosamine 
moiety for the biological activity of nystatin. 
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A gene for putative P450 monooxyganse NysN has been identified in the nystatin 
biosynthesis gene cluster. The function of NysN has been predicted to be oxidation of an 
exocyclic C16 methyl group on the nystatin molecule in order to afford a C16 carboxyl. 
The latter group has been implicated in selective toxicity of other polyene macrolides, and 
thus is considered an important target for manipulation. The nysN gene was inactivated in 
S. noursei by both in-frame deletion and site-specific mutagenesis, and the resulting 
mutants were shown to produce 16-decarboxy-16-methylnystatin, supporting the suggested 
biological role of NysN as C16 methyl oxidase. The recombinant NysN protein was also 
expressed in Escherichia coli, but its C16-methyl oxidase activity in vitro could not be 
demonstrated. 16-decarboxy-16-methylnystatin was purified from the nysN mutant, and its 
antifungal activity was identical with nystatin whereby the toxicity was reduced compared 
to nystatin. 
 
In the work of developing new methods for obtaining nystatin analogues, bioconversion of 
nystatinolide was performed as a means to modify nystatin aglycone. For this purpose a 
sub-library of 35 different Streptomyces strains isolated from the Trondheims fjord was 
selected. One strain was shown to be able to add a water molecule (presumed epoxidation) 
and another strain was able to chlorinate the nystatinolides. An attempt on alternative 
glycosylation of nystatinolide was performed by using glycosyltransferase hybrids and 
deoxysugar biosynthesis gene cassettes. However, these experiments did not afford novel 
nystatin analogues, suggesting strong preference of the NysDI glycosyltyransferase for its 
natural sugar substrate GDP-mycosamine. 
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1. INTRODUCTION 
 
The need for novel, broad-spectrum antifungal agents is increasingly important in today’s 
medical arena due to a significant increase in numbers of immunocompromised patients 
easily affected by fungal infections. AIDS, poor nutrition, the use of broad-spectrum 
antibiotics, indwelling surgical devices, and a variety of treatment regimens such as cancer 
chemotherapy or immunosuppressive therapy prior to transplantation all contribute to the 
growth of this patient population. 
 
An increase of fungal infections of 400 % over the past two decades is reported, those 
caused by frequency of Candida species becoming the most common (43).  The number of 
antifungal antibiotics currently available is limited, and polyene macrolide antibiotics have 
so far proved to be the most effective antifungal agents due to their broad spectrum of 
activity and low frequency of appearance of resistant pathogens. However, polyene 
macrolides are rather toxic, and it is desirable to develop novel antifungals with improved 
pharmacological properties.  
 
 
1.1 HISTORICAL HEADLINES IN THE DISCOVERY OF ANTIBIOTICS 
Human infectious diseases were described already in the Old and New Testaments, as the 
impact of leprosy revealed. It is also known that tuberculosis afflicted Neolithic man 7000 
years ago, but early man did not understand even the basic rules needed to contain the 
diseases. In the VI century an epidemic of plague killed an estimated 100 million people in 
the Middle East, Europe and Asia. Plague, known as the Black Death, has returned during 
the fourteenth century, and is estimated to have killed up to half the population of Europe, 
about 75 million people. Even as late as 300 years ago, when the plague returned from 
London for the last time in 1665, basic procedures to contain the epidemic were not 
implemented (3).  
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As we now enter the third millennium, we are quite privileged having access to an arsenal 
of developed antibiotics, which can kill or inhibit many of the bacteria that can cause 
infection (3). But antibiotics have not always been available; the first searches for 
antibiotics began in the late 1880s, starting with the growing acceptance of the germ theory 
of disease introduced by Louis Pasteur, a theory which directly linked bacteria and other 
microbes to a variety of ailments. As a result, scientists began to search for new drugs, the 
“magic bullets”, that would kill these disease-causing microbes without showing toxicity to 
the patients (160). 
 
1.1.1 Microbial antibiotics to treat diseases 
 
The French biologist Paul Vuillemin was in 1889 the first to use the term antibiosis to 
describe the phenomenon whereby one organism destroys another in order to survive; he 
also used the term antibiote to describe the chemical substance involved. It was Selman 
Waksman, in 1941, who finally provided the definition of an antibiotic, which is still 
accepted today. This stated that ‘an antibiotic is a chemical substance produced by a 
microorganism that has the capacity to inhibit the growth and even destroy bacteria and 
other microorganisms’ (97). 
 
Antibiotics differ from antiseptics in that they are sufficiently selective to allow their use 
within the body, rather than just on the surface, the selective toxicity is not absolute but it is 
quantifiable. Antibiotics that kill the bacteria are called bactericidal, whether they are called 
bacteriostatic if they merely inhibit replication of the bacteria which remain viable and may 
start to grow when the concentration of drugs fall (3). One of the first areas of scientific 
exploration in this field was whether harmless bacteria could treat diseases caused by 
pathogenic strains of bacteria. In 1877, the great microbiologist, Louis Pasteur, 
demonstrated that the bacterial disease anthrax, which can cause respiratory failure, could 
be rendered harmless in animals with the injection of soil bacteria. In 1887, Pasteur and 
Emmerich demonstrated that bacteria actually could treat the disease and in 1888, E. de 
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Freudenreich, isolated the first natural antibiotic (pyocyanase) from a bacterium that had 
antibacterial properties. Unfortunately, pyocyanase proved toxic and unstable, and could 
not be developed into an effective drug. 
 
In 1909 John Ehrlich discovered the arsenic-containing drug ‘606’ (later called 
Salvarsan/arsephenamine), the first true successful anti-syphilitic antibiotic. It was to 
remain the mainstay of treatment until the arrival of another ‘wonder drug’; penicillin 
(Figure 1) discovered by Alexander Fleming in 1928 (97). Penicillin, which was Fleming’s 
second discovery after lysozyme, changed the course of medicine. Penicillin was named 
after the Penicillium fungus that produced it, and Fleming demonstrated that penicillin 
destroyed a common bacterium, Staphylococcus aureus, associated with sometimes deadly 
skin infections. Penicillin was originally discovered by the French medical student Ernest 
Duchesne in 1896. Unfortunately, he failed to report a connection between the fungus and a 
substance that had antibacterial properties, and Penicillium was forgotten until Fleming’s 
re-discovery. Though Fleming discovered penicillin, he was not able to purify it in 
significant quantities. In 1939, H. Florey, E. Chain, and N. Heatley were able to overcome 
the technical difficulties with purifying penicillin, and demonstrated the efficiency of 
penicillin in the clinical setting. From the 1940s the penicillin was produced in increased 
scale, and in 1946 the drug had become widespread for clinical use. 
 
During the period between re-discovery and advancement of penicillin, a few other notable 
findings in the search for antibiotics have been made. Of greater significance was the work 
of Lieske, Gratia and Dath in the 1920s, who independently demonstrated that soil 
microorganisms of the order Actinomycetales could, in most instances, produce 
antibacterial substances. This was demonstrated by inhibition of staphylococcal growth in 
areas inoculated with a strain of actinomycetes (97). In 1932, Gerhard Domagk turned the 
attention towards synthetic antibiotics, chemical dyes, for their effects on bacterial 
infections and found that the dye Prontosil cured diseases caused by the Streptococcus 
bacteria when injected into infected animals. It was later demonstrated that the active 
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moiety of Prontosil was not the dye part of the molecule, but the sulfonamide group 
attached to it. Both Prontosil and other sulfonamide derivates proved highly successful, 
both in efficacy and lack of toxicity. In 1939, the antibiotic gramicidin was isolated from a 
soil-inhabiting microbe. Gramicidin was the first natural antibiotic extracted from soil 
bacteria and was able to arrest the growth of Staphylococcus, but unfortunately proved 
highly toxic for systemic use. 
 
N
S
O
RCONH CH3
CH3
CO2H
CH2
OH CH(NH2)
OMe
OMe
CH
NH2
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Amoxycillin:       R=
Methicillin:         R=
Ampicillin:          R=
 
 
Figure 1: Chemical structures of penicillins. 
 
In 1934, Selman Waksman and his group isolated another antibacterial agent, streptomycin, 
from the soil bacterium Streptomyces griseus. Streptomycin proved effective against 
several common infections. Most noteworthy, was its ability to kill the bacterium 
Mycobacterium tuberculosis, the microbe causing tuberculosis, which had to that point 
resisted numerous methods of treatment. Unfortunately, streptomycin had highly toxic side 
effects and its use induced a fast rate of mutation rendering bacteria resistant to this 
antibiotic, making it inappropriate for clinical use. 
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The first antifungal antibiotic, griseofulvin (Figure 2) (25) produced by Penicillium 
griseofulvum and P. janczewskii Zal was discovered in 1939. Its structure was elucidated by 
Grove and McGowan (1947) (57) and Brian et al. (1949) (25). It is fungistatic and binds to 
cell lipids as well as inhibiting nuclear division. 
 
O
O
O
CH3O
OCH3 OCH3
CH3Cl
Griseofulvin  
Figure 2: Chemical structure of griseofulvin. 
 
In 1945 Lehman designed the drug Para-amino-salicylic acid to inhibit a specific bacterial 
target; this drug was active against most virulent strains of tuberculosis. But already in 
1951, modifications of thiosemicarbazone derivates led to a more active compound against 
the tuberculosis bacillus, this compound was named isonicotininic hydrazide or isoniazid 
(3). 
 
The most productive period of finding and developing antibiotics was between late 1950s 
and mid 1980s, where the main natural antibiotic groups were discovered by the mid 1950s. 
In 1961, an important novel antibacterial chemical nucleus was discovered when the 
nucleus of nalidixic acid (a 4-quinolone) was identified. Many innovative antibiotics have 
since then been variations of old chemical structures (3). Of New Chemical Entities 
(NCE’s) between 1981 and 2002, 90 antibacterials and 24 antifungal compounds were 
reported (112), an overview of the distribution between biological, natural and synthetic 
drugs is given in Table 1. 
 
 
 
 
 5
Table 1: New Chemical Entities of antibacterials and antifungals between 1981 and 2002 
(112). 
Major Categories or Sources Antibacterial 
entities 
Antifungal 
entities 
Biological  1 
Natural Product 9  
Derived from a natural product and usually a semisynthetic 
modification 
61 2 
Totally synthetic drug (random screening/ modification of 
existing drug) 
19 18 
Totally synthethic drug / Natural product mimic  3 
Made by total synthesis, but the pharmacore is/was from a natural 
product / Natural product mimic 
1  
Total 90 24 
 
 
1.1.2 Main classes of antibiotics  
 
The main classification of most antibiotics used today is chemical – here some antibacterial 
and antifungal antibiotics are listed and described (Table 2) (antiviral and antiparasitic 
antibiotics are not included here due to limitations on the scope of this thesis). After 
chemical classification antibiotics can be divided in classes depending on their major 
targets such as cell membranes, cell-wall biosynthesis enzymes and substrates, protein 
synthesis and nucleic acid replication and repair which act via an anti-metabolite 
mechanism (3). For antifungal antibiotics the main targets are sterol biosynthesis, nucleic 
acid and glucan synthesis. The selection of commercial antibacterial antibiotics is still in a 
far higher number then antifungal antibiotics. There have been less success in developing 
drugs that act against fungal infections and only limited success has been achieved in 
discovering antibiotics against viral infections (3). One reason for slow progress in the 
development of antifungal antibiotics compared to antibacterials is that, like mammalian 
cells, fungi are eukaryotes. Agents that inhibit protein, RNA or DNA biosynthesis in fungi 
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will therefore have greater potential for toxicity to the host as well (56). Another reason is 
that until recently, the incidence of life-threatening fungal infections was perceived as too 
low to warrant aggressive research by the pharmaceutical companies (55).  
 
 
1.2 STREPTOMYCES BACTERIA AS ANTIBIOTIC PRODUCERS 
 
1.2.1 The genus Streptomyces 
The genus Streptomyces belongs to the order Actinomycetales which comprise one of the 
two major branches of the Gram-positive bacteria. They are characterized as G/C rich 
organisms often developing mycelia, originally regarded as the hallmark of the 
actinomycetes. Partial sequence analysis of 16S ribosomal RNA is the most significant 
taxonomic tool for defining genera and suprageneric groups of actinomycetes (84). 
The genus Streptomyces can be defined by both genetic and chemotaxonomic 
characteristics such as 16S ribosomal RNA sequence, cell wall composition, fatty acid and 
lipid patterns (163, 167). Streptomyces are ubiquitous in nature and their growth as 
vegetative hyphal mass which can differentiate into spores assisting in spread and 
persistence facilitates their ability to colonize the soil. The spores are a semi-dormant stage 
in the life cycle that can survive in soil for long periods (49, 101) showing resistance to low 
nutrient and water availability, whereas the mycelial stage is sensitive to drought (80). 
Actinomycetes are producers of two-thirds of the known antibiotics produced by 
microorganisms, and nearly 80% of those are made by members of the genus Streptomyces. 
Streptomycetes also produce other classes of biologically active secondary metabolites with 
antitumor, antiparasitic, herbicidal, immunosuppressant activity etc (84). The bacterial 
antibiotic production is believed to have the function of defending the cells from 
competitors at the time of development of the aerial mycelium (36). 
 
 
 
 7
 Table 2: Main antibacterial and antifungal antibiotic classes, examples of drugs, source, 
antimicrobial use and target (3) (pp57-80, 48, 69). 
Antibiotic class Example drug Source Antimicrobial 
use 
Target 
Antibacterial antibiotics     
β-lactams PenicillinG 
Cephalosporin 
Amoxicillin 
P. notatum 
A. chrysogenum 
Semisynthetic 
G+ 
G+ 
G+/G- 
Cell wall 
synthesis 
β-lactamase 
inhibitors 
Clavulanic acid  S. clavuligerus  β-lactamase 
inhibitor 
Glycopeptides 
 
Vancomycin  
Teicoplanin 
S. orientalis  
A. teichomyceticus 
G+ 
G+ 
Cell wall 
synthesis 
Polypeptides Polymyxin B and 
E 
B. polymyxa G- Cell wall 
permeability 
Aminoglycosides Streptomycin S. griseus G+/G- Protein Synthesis 
Macrolides Erythromycin  
Telithromycin 
Sac. erythraea G+/G- 
G+/some G- 
Protein synthesis 
Streptogramins Virginiamycin   S. virginiae (40) G+/some G- Protein synthesis 
Lincomycins Lincomycin  
Clindamycin 
S. lincolnesis 
Semisynthetic 
G+ Protein synthesis 
Tetracylines Tetracycline 
Doxycycline 
S. aureofaciens 
Semisynthetic 
G+/G- Protein synthesis 
Chloramphenicol Cloramphenicol  S. venezuelae G+/G- Protein synthesis 
Rifampicin Rifampicin Amycolatopsis 
mediterranei  
G+/G- RNA synthesis 
Sulphonamides Sulphanilamide Synthetic G+/G- Folic acid 
synthesis 
Trimethoprim Trimethoprim Synthetic G+/G- Folic acid 
synthesis 
Quinolones Nalidixic acid 
Ciprofloxacin 
Synthetic G+/G- DNA replication 
Metronidazole Metronidazole Synthetic Anaerobic DNA replication 
Antifungal antibiotics (168)     
Polyenes 
  
Nystatin   
Amphotericin 
S. noursei (24) 
S. nodosus (30) 
Candidia 
Aspergillus  
Ergosterol, cell 
membrane 
permeabilizin 
Pyrimidine Analogs 
 
Flucytosine Synthetic Candida 
Cryptococcus 
DNA replication 
Azoles 
 
Fluconazole 
Metronidazole 
Synthetic Candida 
Cryptococcous 
 
Ergosterol 
biosynthesis, 
DNA replication 
and transcription 
Echinocandins  
 
Caspofungin Semisynthetic 
Glarea lozoyensis 
Candida 
Aspergillus 
Β-(1,3)-glucan 
biosynthesis 
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1.2.2 Physiology and regulation of antibiotic production 
In Streptomyces the antibiotic production is growth phase-dependent. In liquid culture the 
production starts when the culture enters stationary phase and in agar-grown cultures the 
production coincides with the onset of morphological differentiation  (35). The initiation of 
antibiotic biosynthesis is determined and influenced by a variety of physiological and 
environmental factors, such as growth rate, diffusible γ-butyrolactone signaling molecules 
(72), imbalance in metabolism (70) and various physiological stresses (68, 172). The 
antibiotic synthesis might also be subject to metabolite repression and/or inhibition by 
nitrogen sources (generally NH4+), phosphate and/or glucose (35, 45, 46). 
 
 
1.3 BIOSYNTHESIS OF MACROLIDE ANTIBIOTICS IN STREPTOMYCES 
Secondary metabolites which are not essential for growth tend to be strain specific and have 
a wide range of chemical structures and biological activities. They are derived by unique 
biosynthetic pathways from primary intermediates and metabolites, and these pathways are 
often long and complex; the reactions are catalysed by enzymes with substrate specificities 
different from those of primary metabolism. The formation of secondary metabolites is 
directed by organized clusters of 20-30 genes associated with special regulatory 
mechanisms that seem to control both the timing and the level of gene expression. The 
control mechanisms are well integrated with the physiology of the producing organisms 
(158). 
Examples of secondary metabolites mainly produced by Gram-positive bacteria of the 
genus Streptomyces are polyketides having applied potential as pharmaceuticals. Examples 
of such polyketides are erythromycin (antibacterial), nystatin (antifungal), avermectin 
(antiparasitic), rapamycin (immunosuppressant) and daunorubicin (antitumor). In this thesis 
the focus will be biosynthesis of antifungal antibiotic nystatin.  
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1.3.1 Macrolactone ring assembly 
The genetics and biochemistry of polyketide biosynthesis in Streptomyces bacteria are well 
characterized (71). Macrolide polyketide compounds are formed in a manner similar to 
fatty acid biosynthesis via repeated condensations of simple carboxylic acids by modular 
(type I) polyketide synthases (PKSs). Type I PKS are organized into repeated units 
(modules) (47) where each of them are responsible for one condensation cycle in the 
synthesis of a polyketide chain. Manipulations of type I PKS genes have been performed 
resulting in predictable changes in the chemical structure of macrolides, confirming this 
mode of operation (82). 
Condensation of the next carboxylic acid onto the growing polyketide chain is performed 
by β-ketoacyl synthase (KS) domain. Modules of PKS type I may also contain domains 
with β-ketoreductase (KR), dehydratase (DH), and enoyl reductase (ER) activities that 
determine the reduced state of the incorporated extender unit. In each module 
acyltransferase (AT) and acyl carrier protein (ACP) domains are present responsible for the 
choice of extender unit and retention of the growing polyketide chain on the PKS, 
respectively. By completion of the polyketide chain synthesis, it is released from the PKS 
via the action of a thioesterase (TE). TE is probably also involved in cyclization of the final 
product.  
 
1.3.2 Post-PKS modifications 
Polyketides comprise one of the largest and most diverse groups of secondary metabolites 
produced by various bacteria, fungi, plants, algae and dinoflagelates etc (127). The 
polyketides produced by these organisms comprise antibiotics, antifungals, anticancer 
drugs, immunosuppressants, cholesterol lowering agents, analgesics, antiparasitics, 
neurotoxins (127) and virulence determinants (133). 
The readily synthesized and cyclized polyketide is usually modified via hydroxylation, 
glycosylation, methylation and/or acylation. These post modifications are believed to be 
crucial important for the biological activities of macrolides. Tailoring, or post PKS 
modifications are mostly catalyzed by oxygenases, oxidases, peroxidases, reductases, 
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dehydrogenases and group transferases. They are crucial for the addition of important 
functional groups to polyketide skeletons and are crucial to the structural diversity and 
biological activity of this class of natural products (129).  
 
Oxygenases 
Oxygenases catalyse reactions leading to enormous structural diversity of many PKS 
products, making these enzymes attractive for combinatorial biosynthesis. The most 
common oxygenase types are cytochrome P450 monooxygenase (CYP450), flavin-
dependent mono- and dioxygenase, and anthrone oxygenases, the latter remarkable for their 
lack of requirement of NADPH/NADH or any other cofactor (129). Most macrolide 
antibiotic producing bacterias contain one or more soluble cytochrome P450 
monooxygenases in the antibiotic gene clusters, where the individual cytochromes exhibit 
relatively broad substrate specificity (114). A classical reaction for the cytochrome P450 
monooxygenases is transfer of a oxygen atom from O2 to a variety of substrates by use of 
electrons supplied from NAD(P)H via ferrodoxin (Fdx) and ferredoxin oxidoreductase 
(Fdr) (114). 
 
Group transferases 
The term group transferase refers to enzymes that possess transferase activity introducing 
novel functional groups and altered profiles on the product relative to the substrate. This 
enzyme group contains important enzymes such as amino transferases, alkyl (usually 
methyl) transferases, acyl (usually acetyl) transferases, glycosyltransferases (GTs) and 
kinases. Methyl- and glycosyltransferases are the most important post PKS modifying 
enzymes, (129). 
 
Glycosyltransferases perform perhaps the most important biotransformation on Earth, at 
least in quantitative terms. GTs are responsible for attachment of sugar moieties, often 
deoxysugars, adding important features and properties to a molecule and they often play an 
essential role in the biological activity of many natural product-based drugs (52, 85, 92, 
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104, 153, 170). Some GTs have also shown to have unexpected inherent substrate 
flexibility either towards their acceptor substrate (usually alcohol or phenols) or 
(deoxy)sugar donor co-substrates, and sometimes even to both (50, 89, 171, 173).  
 
Methyltransferases use S-adenosylmethionine (SAM) as cofactor and can methylate O, N 
or C-atoms. O and N-methylations increase the liphophilicity of a molecule and also 
remove hydrogen-bond donor sites. The methylation reactions can occur either at the 
polyketide derived aglycone moiety or on sugar residues, either prior to or after the 
glycosyl transfer (129). 
 
 
1.3.3 Utilisation of post-PKS modifying enzymes in combinatorial biosynthesis 
 
Combinatorial biosynthesis is defined by C. Khosla as to “involve genetically engineering 
biosynthetic pathways in such a way that they may be combinatorially reconstructed to 
produce libraries of novel small molecules that are appropriate for use in screening for new 
drugs” (83).  
Post-PKS tailoring steps are necessary to add functional groups essential for the biological 
activity and are therefore important in the biosynthesis. Targeted gene inactivation of post-
PKS enzymes does not only present a very useful tool for the elucidation of biosynthetic 
pathways by analysis of accumulated intermediates or shunt products, but is also used in 
the context of combinatorial biosynthesis to generate new “unnatural” products with altered 
biological activities. 
To further increase the biochemical variability by orders of magnitude, alterations of 
substrate specificity for enzymes like cytochrome P450 oxidoreductases, methyl 
transferases and glycosyltransferases as well as the heterologous expression of entire 
deoxysugar pathways reinforce the chances of finding novel bioactive polyketide 
compounds with desirable properties.  
GTs are and will become more and more important tools for combinatorial biosynthetic 
approaches (134). The GTs can be used themselves, but glycosidic moieties can be 
modified by altering the biosynthesis of their deoxysugar moieties as well (52, 79, 86, 92, 
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104, 153, 170). A different NDP-sugar will be the outcome of such an experiment and the 
approach is therefore only successful if the natural GTs possesses certain flexibility and can 
therefore also act on the modified NDP-sugar donor substrates. The modification of 
deoxysugar biosynthetic pathways, in the context of combinatorial biosynthesis, always 
goes hand-in-hand with offering foreign NDP-sugar donor substrates to a given GT. 
Genetic manipulation of oxygenase genes provides useful information on the functions and 
characteristics of the encoded enzymes; the ultimate goal being rational design and 
generation of novel hybrid natural products. The progress toward this goal has been slow, 
as many experiments have been and still are conducted in a semi-random mix-and-match 
fashion, especially for post PKS-oxygenases (129). As for GTs, it is also important to 
identify and characterise additional monooxygenases in order to target the increasing 
number of novel polyketides obtained by combinatorial techniques (33, 76, 146). 
 
 
1.4 POLYENE MACROLIDE ANTIBIOTIC GENE CLUSTERS 
 
In recent years the biosynthetic gene clusters for the polyene antibiotics nystatin (Figure 4), 
pimaricin and amphotericin (Figure 3) have been sequenced (6, 24, 30), and the gene 
cluster for candicidin (Figure 3) has been cloned and partially sequenced (74). 
The PKS proteins of polyene macrolide antibiotics have been analysed and studied in some 
detail. Nystatin and amphotericin PKS are highly homologous, which is not surprising as 
the structure of the two polyene macrolides is quite similar. The corresponding PKS 
proteins show ca 72 % sequence identity. The PKS proteins of pimaricin are organized 
along the same lines but certain modules are absent according to the contracted size of the 
macrolactone ring. The candicidin PKS contains 21 extension modules, whereby ten 
modules have been completely sequences. Candicidin is so far the largest aromatic 
heptaene studied (32). 
The polyene macrolides undergoes relatively few post-PKS modifications. They contain 
only one deoxysugar (mycosamine), and a methyl branch is converted to a carboxyl group 
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(116). Whereas amphotericin and nystatin undergoes post-PKS hydroxylation, pimaricin 
undergoes epoxidation. 
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Figure 3: Chemical structures of the polyene macrolides pimaricin, amphotericin and 
candicidin. 
 
1.4.1 The polyene macrolide antifungal antibiotic nystatin  
 
Nystatin, originally named fungicidin, was the first member of the group of polyene 
macrolide antifungal antibiotics discovered by Hazen and Brown in 1950 (64). The 
streptomycete strain identified as a nystatin producer, was characterized in 1953 by 
Ettlinger (27) as Streptomyces noursei named after the farmer (H. Nourse), whose soil 
contained the initial sample. Nystatin, named after the site of discovery; New York State, 
was itself isolated, purified and characterized (65). S. fungicidicus ATCC 27432 has shown 
to produce nystatin and S. albulus ATCC 12757 have also been reported to  produce 
nystatin  (156). However, so far S. noursei is the only strain used for commercial 
production of this antibiotic. 
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As reviewed by Fjærvik and Zotchev (51), S. noursei also produces other biologically 
active compounds in addition to nystatin, such as antifungal cycloheximidine and the 
antibacterials phalamycin and nourseothricin. The nystatin complex contains three related 
polyene macrolides; nystatin A1 (the major component), A2 and A3. Nystatin A3 contains an 
additional L-digitoxose moiety attached at C35 of the nystatin macrolactone, but the 
structure of A2 has so far not been reported (28). 
 
The stereochemical structure of polyene macrolide nystatin (Figure 4) produced by 
Streptomyces noursei ATCC 11455 was completely solved in 1986 (90). It contains a 
polyketide moiety consisting of a 38-membered macrolactone ring with sets of two and 
four conjugated double bonds separated by a saturated bond. Nystatin is classified as a 
tetraene, but because of the two sets of conjugated double bonds it is sometimes referred to 
as “degenerated heptaene” (39). Nystatin, like other polyene macrolide antifungals, also 
contains the deoxysugar mycosamine attached to the macrolactone ring at C19 via a β-
glycosidic bond and an exocyclic carboxy group at C16. Both appear to be important for 
biological activity and toxicity (20). The stoichiometric formula of nystatin is C47H75NO17, 
and the corresponding molecular weight (MW) is 926.5 Da. 
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Figure 4: Chemical structure of nystatin. 
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1.4.2 The nystatin biosynthesis gene cluster  
Macrolide antibiotic biosynthesis genes in Streptomyces are organized in clusters and 
cloning and complete DNA sequencing is described for several macrolide antibiotics 
produced by Streptomycetes, including those for avermectin, pikromycin, rapamycin, 
pimaricin and nystatin (6, 24, 77, 140, 171). 
 
In the 124 kb DNA region of S. noursei containing nystatin biosynthesis genes, there were 
found six genes encoding a modular polyketide synthase (PKS), genes for thioesterase, 
deoxysugar biosynthesis and attachment, post-PKS modification, transport and regulatory 
proteins (24). The gene products from the nystatin cluster and putative or experimentally 
verified functions thereof are listed in Table 3. 
 
PKS modules 
Based on amino acid sequence alignments, comparison with known PKS genes and the 
results of gene disruption experiments, it was suggested that the genes nysA, nysB, nysC, 
nysI, nysJ and nysK encode PKS modules necessary for assembly and cyclization of the 
nystatin macrolactone ring (Table 3, Figure 5) (22, 24).  
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Table 3: PKS genes, Post-PKS modifying genes and regulation and transport genes 
identified in nystatin biosynthetic gene cluster of S. noursei. 
Gene Product Function 
PKS genes   
nysA Type I PKS Nystatin PKS (loading module) 
nysB Type I PKS Nystatin PKS (modules 1 and 2) 
nysC Type I PKS Nystatin PKS (modules 3-8) 
nysI Type I PKS Nystatin PKS (modules 9-14) 
nysJ Type I PKS Nystatin PKS (modules 15-17) 
nysK Type I PKS Nystatin PKS (modules 18 + TE) 
nysE Thioesterase Release of polyketide chain from PKS 
Post-PKS modifying genes   
nysDI Glycosyltransferase Attachment of mycosamine to 
macrolactone  
nysDII Aminotransferase Mycosamine biosynthesis 
nysDIII GDP-mannose-4,6-dehydratase Mycosamine biosynthesis 
nysF 4´-Phosphopantheteine transferase Post-translational PKS modification 
nysL P450 monooxygenase Hydroxylation at C-10 
nysM Ferredoxin Electron transfer in P450 system 
nysN P450 monooxygenase Oxidation of methyl group at C-16 of 
macrolactone  
Regulation and transport genes   
nysRI Transcriptional activator Positive regulator of nystatin biosynthesis 
nysRII Transcriptional activator Positive regulator of nystatin biosynthesis  
nysRIII Transcriptional activator Positive regulator of nystatin biosynthesis 
nysRIV Transcriptional activator Positive regulator of nystatin biosynthesis 
nysG ABC transporter Efflux of nystatin 
nysH ABC transporter Efflux of nystatin 
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Figure 5: Biosynthesis of nystatin macrolactone in S. noursei ATCC 11455. Red arrows 
are PKS proteins, and blue arrows are modules within the PKS module. KSs is ketosynthase 
with Cys → Ser active-site substitution; KS is ketosynthase; AT is acetyltransferase; ACP 
is acyl carrier protein; KR is ketoreductase; DH is dehydratase; ER is enoyl reductase; TE 
is thioesterase and domains prefixed by ”i” are presumably inactive. 
 
NysA is the protein identified to be the nystatin aglycone biosynthesis initiating PKS 
module. The protein contains ketosynthase (KSs), acetyltransferase(AT), dehydratase (DH), 
and an acyl carrier protein domains. The NysA module has been demonstrated to be 
absolutely necessary for the initiation of nystatin biosynthesis via construction of an in-
frame deletion mutant. The role of NysA KSs domain remains unclear, but based on the 
results from site-specific mutagenesis it has been suggested that this domain differs from 
the KSQ domains frequently found in the loading modules of PKS type I systems in that the 
“active site” residue is not significant for its activity (22). It seems as the DH domain has 
no function in NysA, except probably for maintenance of a protein structural integrity, and 
being an evolutionary remnant (22). The sequence of AT domain displays a acetate-specific 
signature (62) containing the conserved Arg117 residue which are typical for such domains 
with high selectivity for CoA esters of dicarboxylic acids (93). It has been demonstrated 
that the KSs domain and AT domain with conserved Arg117 residue are shared by other 
polyene type I PKSs (7, 30). Based on unclear function of the KSs domain for the NysA 
function, it remains unknown whether malonyl-CoA or acetyl-CoA is used as primer for 
nystatin biosynthesis (22).  
 
While the loading modules for most modular PKS systems are fused to the first extender 
module, the loading modules of PKSs for polyene macrolides are unique, as they are 
represented as separate polypetides. This might provide a greater degree of freedom in 
folding of the polyene PKS loading module and probably affect the choice of the starter 
unit by these proteins (22). 
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After loading and chain initiation performed by NysA, elongation is continued by NysB 
(module 1 and 2) performing the first two elongation steps in nystatin polyketide moiety 
biosynthesis using propionate extenders. NysC (six modules) is responsible for elongation 
steps 3-8 incorporating six acetate extenders to the nystatin aglycone. NysI (six modules) 
performs elongation steps 9-14, where module 11 incorporates a propionyl extender. NysJ 
(three modules) is performing elongation steps 15-17. NysK (one module) represents the 
final 18th domain, which contains a TE domain at the carboxyl terminus presumed to be 
responsible for the release of the mature nystatin polyketide chain from the PKS complex. 
Most of the nystatin PKS modules contain both KR and DH domains, but many of the latter 
ones are inactive because of internal deletions or active-site substitutions. This is 
particularly true for modules involved in the assembly of the  polyol region of the nystatin 
molecule (24). ER domains in module 5 and 15 are responsible for the reduction of a 
double bond between C28-C29 and C8-C9, respectively. Downstream of NysC there is also 
found a coding sequence (nysE) for a TE, probably encoding a proof-reading enzyme 
ensuring proper functioning of the PKS complex (24). 
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Figure 6: Model describing the organization of nystatin PKS cluster in S. noursei ATCC 
11455 and the following functions of the genes involved in nystatin biosynthesis. The PKS 
modules are shown in orange (A, B, C, I, J, K); genes involved in post-PKS functions are in 
blue (NysN, NysM and NysL); mycosamine biosynthesis (NysDIII and NysDII) and 
attachment (NysDI) are in green; nystatin export in pink (NysG and NysH); regulation 
(NysRI-RIV) and editing/maintenance of polyketide synthesis (NysE) in red. 
 
Post-PKS modifications 
Based on the structure and organization of the PKS genes in the nystatin biosynthesis gene 
cluster, it is suggested that at least three post-PKS modifications are required to convert the 
nystatin macrolactone ring into nystatin. These modifications are represented by formation 
of a glycosidic bond at C19 between the aglycone and mycosamine, oxidation of a C16 
methyl group to a carboxyl and C10 hydroxylation. It is suggested that the oxidation of C16 
comes first in a series of post-PKS modifications supported by the fact that nystatin 
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precursors lacking the carboxyl group at C16 but possessing a C10 hydroxyl and/or a 
mycosamine moiety has only been identified in trace amounts in S. noursei extracts (28). 
 
Two genes found in nystatin biosynthesis gene cluster, nysL and nysN, encode cytochrome 
P450 monooxygenases, where NysL is responsible for hydroxylation of C-10 (159) and 
NysN for oxidation of C-16 (Paper 3). The nysM gene apparently encodes a ferredoxin 
presumably constituting a part of one or both P450 monooxygenase systems serving as an 
electron donor (114). The three genes putatively responsible for mycosamine biosynthesis 
and attachment nysDI, nysDII and nysDIII show homology to other mycosamine 
biosynthesis genes as for the macrolide antibiotics amphotericin, candicidin and pimaricin 
produced by S. nodosus, S. griseus and S. natalensis (110). Each of the four polyene 
macrolide gene clusters were found to contain a gene for GDP-mannose 4,6-dehydratase – 
amphDIII, canM, nysDIII and pimJ, and it has been suggested that mycosamine is 
synthesized via GDP-D-mannose. GDP-D-mannose is presumably synthesized from 
fructose 6-phosphate by enzymes involved in primary metabolism as the genes for its 
biosynthesis have not been found in the polyene gene clusters. A pathway from GDP-D-
mannose to GDP-mycosamine would involve the GDP-D-mannose 4,6-dehydratase, a 3,4 
isomerization to give GDP-3-keto-6-deoxy-D-mannose, followed by transamination to form 
GDP-mycosamine. A gene that might encode a GDP-4-keto-6-deoxy-D-mannose 3,4-
isomerase has not yet been found in any of the polyene macrolide biosynthesis gene 
clusters characterized so far. It is therefore presumed that GDP-4-keto-6-deoxy-D-mannose 
can isomerize to GDP-3-keto-6-deoxy-D-mannose spontaneously, in the absence of a 
conventional enzyme (5). All four polyene macrolide gene clusters encode 
aminotransferases (AmphDII, CanA, NysDII, and PimC) with homology to various 
perosamine synthases that convert GDP-4-keto-6-deoxy-D-mannose to GDP-perosamine 
(16, 126). For proposed biosynthetic pathway of mycosamine see Figure 7. 
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Figure 7: Proposed biosynthetic pathway for mycosamine and attachment to nystatin 
macrolactone ring. 
 
Regulation of nystatin biosynthesis and its transport 
Regulatory genes: In the S. noursei nystatin biosynthesis cluster four putative regulatory 
genes, nysRI, nysRII, nysRIII and nysRIV, have been identified. By gene inactivation and 
complementation experiments Sekurova et al. (141) have demonstrated that all four genes  
were necessary for efficient nystatin biosynthesis. In the control of nystatin production, 
nysRI is more important then nysRII and nysRIII, as the inactivation of the latter genes has 
had less effect on antibiotic production then inactivation of nysRI. NysRI regulates an 
endogenous promoter of its own gene, which also seems to be controlling the expression of 
nysRII and nysRIII.  These three genes seem to be regulating the expression of NysRIV 
protein, which is suggested to be a transcriptional activator for the nystatin structural genes.   
 
Transporter genes: Two genes, nysH and nysG, encoding putative ABC-type transporters 
were found in the nystatin biosynthesis gene cluster of S. noursei (24). Individual 
inactivation of both of these genes performed by Sletta et al. (144) has led to reduced level 
of nystatin production and accumulation of considerable amounts of the nystatin precursor 
10-deoxynystatin, lacking a hydroxyl group at C-10. Both nystatin and 10-deoxynystatin 
were transported out of the cell, indicating an existence of an alternative efflux system. In 
experiments with ATPase inhibitor (sodium-o-vanadate) the production of nystatin and 10-
deoxynystatin were affected in different manner suggesting that several transporters for 
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nystatin-related polyene macrolides exists and that the NysH-NysG efflux system provides 
conditions favorable for C10-hydroxylation. 
 
 
1.4.3 Glycosyltransferases; post-PKS modifying enzymes     
Glycosyltransferases (GTs) comprise a superfamily of enzymes catalyzing the transfer of 
monosaccharide moieties to biological substrates such as proteins, lipids and carbohydrates. 
GTs are present in all organisms studied, from prokaryotes to humans, and are found in 
every cellular compartment. The carbohydrate components are often vital for survival of 
the organism as they have specific roles in cell-growth and cell-cell interactions (42), cell 
adhesion including fertilization (1, 151), modulation of growth factor receptors (150), 
immune defense (135, 136), inflammation (94), and both viral and parasitic infections 
(137). 
 
Members of the GT superfamily are named after the sugar moiety that they transfer. The 
linkage generated between the donor and acceptor is of importance for dividing GTs into 
subfamilies. Transfer of sugar residue occurs with either retention (by retaining GTs) or the 
inversion (by inverting GTs) of the configuration at the anomeric C1 atom (Figure 8) (143).  
Specific enzymes can be classified based on the reaction catalyzed and the substrate 
specificity, according to the recommendations of the International Union of Biochemistry 
and Molecular Biology (IUBMB) (17). However, the system does not indicate the intrinsic 
structural features of the enzymes, or adequately accommodate enzymes which act on 
several distinct substrates (31). 
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Figure 8:  The glycosyl transfer reaction can occur both as inversion or retention of the 
anomeric configuration of the donor. Glycosyltransferases use sugar donors where the 
active group typically is a (substituted) phosphate as nucleotide (R = nucleoside 
monophosphate), nucleoside monophosphate (R = nucleoside) or lipid phosphate (R = 
lipid). The acceptor, HOR’, is varied and R’ can both be a sugar, a lipid, a protein, an 
antibiotic, nucleic acid etc. 
 
The structures of proteins are better conserved than their amino acid sequences (66). 
Among members in each subfamily there is found sequence homology, but there is no 
sequence similarity between the subfamilies (123). The structural and functional diversity 
in combination with distant evolutionary relationships between GTs contributes to the 
explanation of the low sequence homology between the GTs. On the other hand, the 
majority of GTs belong to only two structural superfamilies named GT-A and GT-B 
superfamilies (21, 154), but still more and more enzymes belonging to other families are 
being discovered. 
 
The structures of the catalytic domains of several GTs have been determined by X-ray 
crystallography. These studies have revealed a structural basis for ordered binding of the 
donor and acceptor, and for the proposed catalytic mechanism of the enzymes (13, 111, 
124, 125, 154). Even if GTs have significant sequence diversity, some have a great 
structural similarity (73). They mainly consist of globular proteins with two types of fold 
termed GT-A and GT-B. Enzymes of GT-A fold comprise two dissimilar domains: the N-
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terminal domain which is involved in nucleotide binding and comprise several β-strands 
that each are flanked by α-helices as in a Rossman-like fold, and the C-terminal domain 
which binds the acceptor and mainly consists of mixed  β-sheets. The GT-B fold enzymes 
are characterized by two similar Rossman fold subdomains (21), where the N-terminal 
domain provides the acceptor binding site, and the C-terminal domain provides the donor 
binding site. The two domains in both GT-A and GT-B fold enzymes are connected by a 
linker region, and the active site is located between the two domains (123).  
 
Some, but not all, GT-A enzymes require binding of a cofactor (often Mg2+ or Mn2+) (123). 
Those enzymes that need cofactors often contain a three residue side chain DXD (Asp-X-
Asp) or an equivalent motif involved in the binding of the metal ion (166). Some GT-B 
enzymes also need metal ion cofactors, but most do not and thus GT-Bs lack a DXD motif 
or it is equivalent (123), which further distinguish them from GT-A proteins. Members of 
the GT-B superfamily have a specific pattern of proline and glycine residues located within 
the donor-binding domain (73). 
 
The GT-B superfamily includes most of the prokaryote enzymes that glycosylate secondary 
metabolites to produce biologically active natural products such as erythromycin, 
daunomycin, vancomycin, novobiocin (165) and nystatin (http://afmb.cnrs-
mrs.fr/CAZY/fam/GT1.html). The GT-B superfamily shares highly conserved two-domain 
architecture, and by comparing structures and sequences of different family members it is 
possible to identify the regions that determine substrate selectivity. The longest conserved 
motif is located in the donor binding domain and encodes a folding unit involved in binding 
the glycosyl donors (73).  
 
NDP-Hexose Formation and GT-Mediated Transfers 
Antibiotics are most often glycosylated  late in the biosynthetic pathway following PKS 
assembly of the aglycone, as in erythromycin or daunomycin-producing actinomycetes (53, 
147). For GTs the general stoichiometry would be as follows: a TDP-hexose is the donor 
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substrate undergoing nucleophilic attack by a hydroxyl moiety on the aglycone. The 
universal biological reagents for hexosyl transfer, the NDP sugars, display the C1 position 
of the sugar activated by the nucleoside diphospho moiety. The nucleoside diphospho 
moiety functions as a low-energy leaving group in GT-catalyzed reactions. Essentially all 
GT-catalyzed reactions therefore involve capture of the glycosyl substrate at the 
electrophilic C1 locus. 
 
TDP-glucose and GDP-D-mannose are common starting points for NDP sugar 
modification, resulting from TTP and GTP pyrophosphorylase activity on sugar-1-P 
substrate (78). Most antibiotic biosynthetic gene clusters contain genes encoding enzymes 
for catalysis of the modification of TDP-D-glucose to afford TDP-deoxy and TDP-
aminodeoxy sugars (161). 
 
Two general characteristics of antibiotic GTs are noteworthy. First, the late timing of GT 
action in the antibiotic biosynthetic processes makes these enzymes amenable for 
reprogramming and/or combinatorial biosynthetic approaches. The introduction of 
structural diversity late in the biosynthetic pathway can potentially lead to novel functions 
in new antibiotics. Second, the vast majority of GTs catalyze activated hexosyl transfer to 
hydroxyl substituents on co-substrate aglycones; however, amine and carbon nucleophiles 
exist such as those found in rebeccamycin biosynthesis (139) and in urdamycin 
biosynthesis.  
 
1.4.4 Cytochrome P450 monooxygenases; post-PKS modifying enzymes 
 
Cytochrome P450s are most often represented by monooxygenases containing 
protophorphyrin IX as their heme group. They are b-type cytochromes and are named by 
the Fe2+-carbon monoxide complexes that show an absorption maximum at 450 nm when 
complexed with carbon monooxide. This characteristic is attributable to an absolutely 
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conserved cysteine residue which  provides the iron-sulphur bond anchoring the heme in 
the active site (54, 87, 118, 119).  
 
The cytochrome P450s, also named CYPs was first experimentally discovered in 1955 (9, 
26). The cytochrome P450s, comprises a whole superfamily of proteins with extremely 
diverse functions, and is described as “the most versatile biological catalyst known”. 
Although having the same basic structure and chemistry, these enzymes perform an 
enormous range of oxidation reactions on a wide variety of physiological and non-
physiological compounds in organisms as diverse as mammals, archae, bacteria, fungi and 
plants (98, 109). In most prokaryotes the cytochrome P450s are soluble and confer the 
ability to catabolize compounds used as a carbon source or to detoxify xenobiotics. Other 
functions include fatty acid metabolism and biosynthesis of antibiotics (164). 
 
Catalytic mechanism of CYP 
Cytochrome P450s catalyze the monooxygenation of a vast array of molecules by 
transferring one oxygen atom from O2 into various substrates in the following reaction: 
 
R-H + NAD(P)H + O2 + H+ → R-OH + NAD(P)+ + H2O 
 
Electrons in this reaction are transferred from NAD(P)H to the cytochrome P450 heme 
group via a redoxin (electron transfer protein) containing either FMN (flavin 
mononucleotide) or Fe2S2 as a cofactor (102). 
 
Classes of cytochrome P450s  
Traditionally, cytochrome P450s were grouped in two classes based on the type of redox 
partners being utilized (how electrons are delivered from NAD(P)H to the active site). 
Lately, more cytochrome P450s have been discovered and the number of classes have 
increased (102). More then 500 different cytochrome P450 genes have been cloned up to 
date. These have been organized into a P450 gene ‘superfamily’ based on their degree of 
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relative homology. The superfamily is divided into gene families where the members 
generally share ≥40 % identity. Members of different families have sequence similarity  
<40 % (109). 
 
Class I is represented by bacterial and mitochondrial cytochrome P450s, where electrons 
are shuttled from NADPH to a FAD-containing ferredoxin reductase, which again reduces 
a Fe2S2 redoxin that binds and transfers electrons to the P450 (75). In class II microsomal 
cytochrome P450s use a single FAD/FMN protein called cytochrome P450 reductase that 
shuttles electrons from NADPH to the cytochrome P450 heme (157). In the third class, the 
cytochrome P450s use a fused FMN and Fe3S4 electron donor protein as a reductase that is 
linked to the C-terminal end of the cytochrome P450 (130). The fourth class represents a 
cytochrome P450 from Citrobacter braakii (P450cin) that has recently been found to utilize 
FAD- and FMN-containing proteins. In contrast to the microsomal cytochrome P450s, the 
FMN and FAD proteins are separate polypeptides  (102). In a fifth class cytochrome P450s 
that does not require a redox partner for activity are grouped together (102). 
 
Structure 
The structures of cytochrome P450 substrate complexes are quite diverse with respect to 
the substrate structure. The structures have provided important insights into the range of 
variations required in the active site to achieve substrate selectivity, and there are no 
structures of cytochrome P450s published where the substrates are very similar (102). 
According to the variety of reactions catalyzed, the size of their substrate varies. Some 
cytochrome P450s have open active sites and some have shielded active sites that open only 
transiently, whereas others bind the substrate only when attached to carrier proteins (122). 
The cytochrome P450 overall fold and topologies are quit similar (61). The general 
structure of cytochrome P450s consists of 14 α-helixes named A to L and 5 β-sheets that 
form a triogonal-prism-shaped molecule with predominately α-helical and β-structured 
parts (121).  
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Cytochrome P450s involved in biosynthesis of macrolides 
Cytochrome P450 genes are found in a number of macrolide biosynthesis gene clusters. 
They catalyze the site-specific oxidation of  the precursors to many macrolide antibiotics, 
such as erythromycin (63, 145, 162), tylosin (105), oleandomycin (131), nystatin (24, 159), 
amphotericin (30), pimaricin (7) candicidin/FR-008 (32, 37). In all reported cases these 
cytochrome P450s act late in the biosynthesis, after the formation of the macrocycle by 
polyketide synthase (PKS). Post-PKS modification by cytochrome P450s often constitutes 
an important contribution to the biological activity of the final molecule (14, 103). 
The amphotericin, nystatin and pimaricin gene clusters each contain two cytochrome P450 
genes each. pimG, amphN and nysN gene products apparently catalyse oxidation of a 
methyl group leading to formation of the exocyclic carboxyl that is characteristic for these 
polyene macrolides (5). Whereas amphotericin and nystatin undergo hydroxylation in the 
polyol region, pimaricin undergoes an epoxidation. The ampL and nysL gene products 
represent hydroxylases acting on the polyol region of their respective polyene 
macrolactones (103). The cytochrome P450 epoxidase PimD catalyses the C4-C5 
epoxidation of 4,5-de-epoxy-pimaricin to pimaricin. PimD, AmphL and NysL belong to the 
same phylogenetic group responsible for specific oxidations in the polyol region of polyene 
macrolide precursors (5). 
 
 
1.5 THE MOLECULAR MECHANISM AND ANTIFUNGAL ACTION OF 
POLYENE MACROLIDES 
 
1.5.1 Permeabilization of biological membranes 
Polyene macrolide antibiotics consist of 20-44 membered lactone rings containing three to 
eight conjugated double bonds. The conjugated double bonds are crucial for the mode of 
action of these antibiotics, since they are involved in interaction with fungal membrane 
sterols (19). The polyene antibiotic molecules form complexes with the membrane sterols 
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to create hydrophilic channels (44) through which Na+ and K+ ions can leak out, eventually 
leading to fungal cell death (60).  
 
The polyene macrolides have been shown to have a higher binding affinity to ergosterol, 
which is the main sterol component in the fungal membrane, than to cholesterol present in 
the mammalian cells (Figure 9). The fact that they bind ergosterol better has been exploited 
in therapeutic use of polyene macrolides (152). Glycosylated polyenes have a better 
activity/toxicity ratio compared to non-glycosylated polyene macrolides, probably because 
non-glycosylated polyenes form larger and more harmful channels in the biological 
membranes, and induce gross membrane fragmentation. Because of this, only glycosylated 
polyenes are currently being used in human therapy (19, 106).  
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Figure 9: Chemical structure of membrane sterols; cholesterol is found in human cell 
membranes, and ergosterol is found in fungal cell membranes. 
 
Among glycosylated polyenes, the molecular mechanism of action is best studied for 
amphotericin. Amphotericin associates with sterols to form barrel-stave type pores (11, 
100), and it has been found that the barrel consists of eight molecules arranged in a quasi-
parallel orientation, with the polyol parts of the molecules pointing inward to constitute the 
pore lining, and the lipophilic heptaene part directing outward to interact with the 
membrane sterols (4, 44). 
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Figure 10: A: Demonstration of polar and nonpolar, chromophore and polyol region of 
nystatin. B: Schematic presentation of a glycosylated polyene macrolide antibiotic 
molecule. 
 
Two such channels are thought to align head to head to span the cell membrane, with the 
mycosamine moieties extending towards the cytoplasmic and extracellular spaces. In these 
studies it has also been demonstrated that the ionizable carboxyl and amino groups are 
important for the activity of the molecule. The basis for this was suggested to be  
interaction, via hydrogen bond formation, between the amino group of mycosamine on one 
antibiotic molecule and an exocyclic carboxyl on the adjacent molecule (Figure 11) (11).  
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Figure 11: Chemical structures of nystatin (red) and ergosterol (black) with the hydrogen 
bond formation between the amino group of mycosamine and exocyclic carboxyl group and 
the ergosterol in channel formation marked with lines. 
 
In a prediction of the mechanism for polyene-membrane complex formation the initial step 
is supposed to be the contact between the antibiotic aggregates and the outer surface of the 
membrane where hydrogen bonds between the phosphate groups in the polar heads of the 
membrane phospholipids and polyene macrolides are formed (107, 169). The next step 
would be the formation of the polyene-membrane complex and depending on the presence 
of sterols in the bilayer. It is suggested that the polyol regions of the molecules engaged as 
dimers form hydrogen bonds with the phosphate groups on the phospholipids, thus 
triggering the turning of dimmers inside out (107). Whether the antibiotic aggregate 
penetrate the membrane or not seems to be depending on the membrane sterol content. 
Thus, the affinity to sterols seems to be mainly responsible for the membrane penetration 
by the polyene aggregates, which then complex with sterols and arrange themselves into the 
channels (174). 
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Figure 12: Demonstration of the formation of the membrane channel in the fungal cell 
membrane by polyene macrolide antibiotics interacting with ergosterol. The channel 
consists of eight molecules arranged in a quasi-parallel orientation, with the polyhydroxy 
side pointing inward to constitute the pore lining and the lipophilic heptaene part directing 
outward to interact with the membrane interior. 
 
1.5.2 Conformation-activity 
By comparative analysis it has been demonstrated that the activity of amphotericin is 6 
times higher than nystatin against most fungi (8). This observation is in line with the 
findings showing that the ion conductance of the channel formed by nystatin is 
approximately 10 times lower compared to that formed by amphotericin (81). As the 
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chemical structures of these two antibiotics are quite similar, the higher affinity of 
amphotericin toward ergosterol is often explained by the presence of an additional 
conjugated double bond, allowing the molecular proximity necessary to maximize the van 
der Waals interactions between amphotericin and sterols (34, 91).  
 
Previously, it was suggested that the arrangements between the amino-sugar moiety and the 
macrolide ring are largely dominated by two conformations. These two conformers are 
described as open and closed where the positions of the amino-sugar are defined by φ and ψ 
dihedral angels, where φ is C1´-O-C19-C18 and ψ is C2´-C1-O41-C19. In the open 
conform φ is about 150o and ψ is 180o, and closed conform φ is about 60o and ψ is 180o 
(10). In the open conform; the amino and carboxyl groups probably form an intermolecular 
hydrogen bond with the complementary carboxyl and amino groups of the neighboring 
amphotericin molecules, thus facilitating amphotericin-amphotericin interactions. The 
closed conform is probably responsible for the formation of an intramolecular hydrogen 
bond between the carboxyl and the amino group (100). 
 
It has been demonstrated that while modification of the amino group decreases the 
antifungal activity, the carboxyl group substitutions had little effect on this property (38). 
Matsumori et al. (100) have shown that the relative position of mycosamine to a macrolide 
ring moiety have a strong influence on the sterol selectivity in channel activity of 
amphotericin. This has been demonstrated by using conformation restricted derivates of 
amphotericin, where the complex shows variable ergosterol selectivity depending on the 
orientation of the mycosamine. A derivate where the mycosamine is twisted with respect to 
the macrolide has higher selectivity for ergosterol then a derivate where the mycosamine 
adopts a parallel orientation with respect to the macrolide ring  (100). Rather small 
conformation alterations of mycosamine can be attributable for the sterol preference of 
amphotericin (100). 
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The sterol dependence of membrane permeabilizing activity of amphotericin has so far 
been explained by different binding affinity between the antibiotic molecule and sterols 
(67, 91). The affinity is probably a result of two types of interactions; 1) a hydrogen bond 
between 3β-OH of the sterol and the amino-sugar moiety of amphotericin either directly or 
mediated by water molecules (10, 12, 67, 91); 2) van der Waals interactions between 
amphotericin heptaene chromophore and hydrophobic steroid rings (34, 91). 
 
 
1.6 APPLICATIONS OF POLYENE MACROLIDE ANTIBIOTICS IN HUMAN 
THERAPY 
Fungal infections represent a growing problem due to the rapid increase in numbers of 
immunocompromized patients. Changes in medical technology, diseases or factors as HIV, 
certain types of anticancer chemotherapy and administration of immunosuppressive drugs 
after organ transplantation make this group of patients especially prone to life-threatening 
invasive mycoses.  
 
Fungi constitute a group of about 250,000 species, whereby  more than 300 species have 
been reported to be potentially pathogenic to humans (58). Aspergillus, Candida, 
Cryptococcus, Cladosporium, Microsporum and Trichophyton spp  are causing 
approximately 90 % of human fungal infections (43, 120). Dasgupta (43) reports a 400 % 
increase in the incidences of fungal infections over the past two decades.  
 
Antifungal agents now constitute 15-16 % of the total market in the infective medicine area 
(43); and it is reported that the market for the antifungals will be expanding at a rate of  7,8 
% per annum (Business Communications Co, March 2003). Although synthetic drugs 
contribute to a major proportion of the antifungals used, antifungals based on natural 
products, such as polyene macrolides, also take a considerable share  in the actinomycotic 
market (41). The need for new, safe and more effective antifungals remains one of the 
major challenges to the pharmaceutical industry today (59). 
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 Polyene macrolide antibiotics have proved to be very effective antifungal agents due to 
their broad spectrum of activity and low frequency of appearance of resistant pathogens. 
Amphotericin is often the treatment of choice of many mycosis cases, but problems with 
toxicity, resistance and non-availability of an orally absorbable form are important 
drawbacks. Since the polyene macrolides nystatin and amphotericin were discovered in 
1950s (64, 148), more than 200 other polyene macrolides with antifungal activity have been 
discovered (117). However, only amphotericin, nystatin, candicidin, pimaricin, methyl 
partricin and trichomycin are currently being used in human therapy. Polyene macrolides 
are in fact rather toxic, and may cause serious side effects such as renal tubular damage and 
thromobophletitis, especially upon intravenous administration (96). The toxicity can 
probably be explained with the affinity of polyene macrolides to the cholesterol in the 
mammalian cell membrane. New polyene macrolide derivates, formulations and ways of 
administrations aimed at reducing toxicity are under development. Some polyenes have 
been shown to inhibit HIV replication, to hamper the development of prion-related 
diseases, and to be useful in cancer therapy as well (174). The development of novel 
polyene macrolide analogs and further investigation into their structure-function 
relationship is necessary in order to reduce the toxicity and improve certain 
pharmacological properties of these compounds (174). 
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2. AIMS OF THE STUDY 
 
Considering the fact that systemic fungal infections is an increasing medical problem due to 
a growing number of immunocompromised patients and a slow pace in development of 
new antifungal drugs, research aimed at discovering more active and less toxic antifungal 
antibiotics is necessary. Nystatin is a commercial polyene macrolide antibiotic used to treat 
superficial fungal infections. Unfortunately, it is too toxic to be used against systemic 
infections as it can cause renal failure, hypokalemia and thrombophlebitis. 
 
Prior to the present study, a gene cluster encoding the biosynthetic pathway for antifungal 
macrolide antibiotic nystatin in Streptomyces noursei has been cloned and sequenced in our 
laboratory. One aim with the current study was to deepen our understanding of the nystatin 
biosynthesis, more specifically, the post-PKS modification steps. Another aim was to 
afford production of new nystatin analogues through inactivation of the post-PKS 
modification genes.  
As these modifications have been proposed to be important for the activity and toxicity of 
the polyene macrolide antibiotics, I have in this thesis investigated the post-PKS 
biosynthesis genes in the nystatin gene cluster presumably involved in mycosamine 
biosynthesis and oxidation of the exocyclic methyl group.  
 
Through chemical modification and testing of the resulting analogues, the mycosamine 
moiety of some polyene macrolides has shown to be important for their biological activity. 
It is presumed that it has an important function in channel formation in the fungal 
membrane. The aim was to confirm the functions of the three genes predicted to be 
involved in mycosamine biosynthesis and attachment in the nystatin biosynthesis. In 
addition, I aimed at confirming the importance of mycosamine for the biological activity 
and toxicity of nystatin. 
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A gene for cytochrome P450 monooxygenase NysN identified in the nystatin biosynthetic 
gene cluster have been predicted to perform oxidation of the C16 exocyclic methyl group 
on the nystatin molecule. The resulting carboxyl has been implicated earlier in selective 
toxicity of polyene macrolides. My aim was to confirm the role of NysN and to obtain 
novel nystatin analogue having C16 methyl group instead of the carboxyl. I was also 
intended to study the biological activity of this new analogue.  
 
In addition, I aimed at discovering new ways for modifications of the nystatin or its 
aglycone by means of bioconversion, construction of hybrid glycosyltransferase genes and 
expression of heterologous deoxysugar biosynthetic genes in S. noursei. 
 
All these studies may be crucially important for obtaining novel nystatin analogues with 
improved pharmacological properties.  
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3 SUMMARY OF RESULTS AND DISCUSSION 
 
3.1 BIOSYNTHESIS OF DEOXYAMINOSUGARS IN ANTIBIOTIC-PRODUCING 
BACTERIA (PAPER 1) 
 
Deoxyaminosugars comprise an important class of deoxysugars synthesized by a variety of 
different microorganisms; they can be structural components of lipopolysaccharides, 
extracellular polysaccharides, and secondary metabolites such as antibiotics. Genes 
involved in the biosynthesis of the deoxyaminosugars are often clustered and are located in 
the vicinity of other genes required for the synthesis of the final compound. Most of the 
gene clusters for aminosugar biosynthesis have common features, as they contain genes 
encoding dehydratases, isomerases, aminotransferases, methyltransferases, and 
glycosyltransferases. In the present mini-review, the proposed biosynthetic pathways for 
deoxyaminosugar components of both macrolide and non-macrolide antibiotics are 
highlighted. The possibilities for genetic manipulations of the deoxyaminosugar 
biosynthetic pathways aimed at production of novel secondary metabolites are discussed. 
 
 
3.2 MYCOSAMINE BIOSYNTHESIS (PAPER 2) 
 
Two genes putatively involved in mycosamine biosynthesis (NysDIII and NysDII) and one 
in attachment of mycosamine to the nystatin aglycone (nysDI) have been identified in the 
nystatin gene cluster of Streptomyces noursei ATCC 11455. NysDIII was suggested to be 
responsible for the conversion of GDP-D-mannose to GDP-4-keto-6-deoxy-D-mannose, 
NysDII was supposed to be an aminotransferase, and NysDI a glycosyltransferase (24). To 
confirm the functions of nysDIII in the mycosamine biosynthesis the protein was expressed 
heterologously and its function was confirmed in an enzyme assay. The nysDII and nysDI 
genes were individually deleted from the chromosome by double homologous 
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recombination and the nysDII and nysDI genes further expressed in-trans in the two 
mutants, respectively. 
 
3.2.1 nysDI and nysDII in-frame deletion and complementation 
The glycosyltransferase NysDI, suggested to be responsible for the attachment of 
mycosamine to the nystatin aglycone, was inactivated by in-frame deletion through double 
homologous recombination, yielding the nysDI deficient mutant NDD1. NDD1 was 
producing nystatin aglycone, nystatinolide (MW780) at 28 % (± 2), 10-deoxynystatinolide 
(MW764) at 63 % (± 4) and nystatin 1.2 % (± 0.2) relative to the nystatin production level 
in the wild type strain. By complementation of the NDD1 mutant with a single copy of  
nysDI expressed under ermE*p promoter, the nystatin biosynthesis was restored to 55 % (± 
5) relative to nystatin production level in wild type, confirming the suggested function of 
NysDI as glycosyltransferase, attaching mycosamine to nystatin aglycone. Simultaneously, 
the production level of nystatinolides which was higher in NDD1 then in wild type was 
noticeably reduced. A lower production of nystatin by the complemented mutant is 
probably not surprising, considering that the nysDI gene was expressed in trans, and from a 
heterologous promoter.  
 
The aminotransferase NysDII, presumed to introduce the amino group of mycosamine 
during the mycosamine biosynthesis, was inactivated by in-frame deletion through double 
homologous recombination, yielding the nysDII deficient mutant NDD2. NDD2 was 
producing nystatinolide at 0.31 % (± 0.15), 10-deoxynystatinolide at 0.09 % (± 0.15) and 
nystatin at 0.05 % (± 0.02) relative to the nystatin production in wild type. The production 
levels were surprisingly low, and by complementation the nystatin production was only 
partially restored to 0.26 % (± 0.12), whereby the production level of nystatinolide was 
reduced to 0.03 % (± 0.01). Although the very low production level, the nystatin production 
is increased by complementation and the nystatinolide production level is reduced 
confirming the suggested function of NysDII in mycosamine biosynthesis. Based on these 
results we suggest that the NysDI glycosyltransferase has a strong preference for GDP-
 41
mycosamine as a substrate.  It is still not clear why the level of the nystatinolide production 
is low in the nysDII mutant compared to the nysDI-deficient strain. One explanation could 
be that NysDII is a structurally important part of the nystatin biosynthetic complex, and that 
absence of NysDII prevents its efficient assembly and functioning. However, 
complementation would have alleviated this problem, which was apparently not the case. 
One hypothesis may be that intermediate(s), appearing as a result of inactivation of nysDII 
might somehow have a negative effect on nystatin biosynthesis. 
 
3.2.2 Antifungal and hemolytic activity of nystatinolides 
In order to confirm the importance of mycosamine for antifungal activity of nystatin, 
minimal inhibitory concentration (MIC50) values were determined for both nystatinolide 
and 10-deoxy nystatinolide produced by S. noursei NDD1. As test organism, Candida 
albicans ATCC 10231 was used. The MIC50 value for nystatinolide was measured to be 60 
μg/ml, for 10-deoxynystatinolide 20 μg/ml and for nystatin 1.2 μg/ml. The amino group on 
mycosamine is presumed to play an important role in interactions between polyene 
macrolide molecules, which organize themselves into channels spanning the cellular 
membrane of the target organism (174). Apparently, the antifungal activity of both 
nystatinolides was significantly reduced compared to nystatin, confirming an importance of 
mycosamine for the biological activity. Interestingly, the antifungal activity of 10-
deoxynystatinolide was higher than that of nystationolide (lower MIC50 value). Considering 
the fact that MIC50 values for nystatin and 10-deoxynystatin are identical (159), it is 
tempting to speculate that the mechanism behind antifungal activity of nystatin aglycones 
differ from that of nystatin.  
 
In order to test the toxicity of the new derivatives in vitro, their hemolytic activity was 
measured in comparison with that of the nystatin. The results of these experiments showed 
that both 10-deoxynystatinolide and nystatinolide had more than 90 % reduced hemolytic 
activity compared to the parental molecule nystatin under the conditions tested (data not 
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shown, see Materials and methods for details). These results indicate that the mycosamine 
sugar moiety contributes significantly to the hemolytic activity of nystatin in vitro.   
 
The fact that both nystatin aglycones displayed greatly reduced hemolytic activity 
compared to nystatin suggests that these molecules fail to form stable channels in the 
eukaryotic cell membranes. The latter is probably due to the lack of efficient interaction 
between the molecules, which probably is ensured through formation of hydrogen bonds 
between carboxy and amino groups of the neighboring molecules (11).  
 
3.2.3 Recombinant expression of NysDIII in E.coli and verification of GDP-D-mannose 
4,6-dehydratase activity in vitro 
 
Inactivation of the nysDIII homologue amphDIII, presumably also encoding a GDP-
mannose 4,6-dehydratase, has previously been performed  in the amphotericin producer 
Streptomyces nodosus, and the resulting mutant produced amphotericin aglycone (29). For 
confirmation of the function of nysDIII, this gene was instead expressed in Escherichia 
coli, purified and used in enzyme assays to confirm the activity of its product. NysDIII and 
NysDII were expressed in commercial expression vectors containing both Flag- (Sigma-
Aldrich) and His-tag (QIAGEN). NysDIII was successfully expressed with Flag-tag located 
C-terminally, and with His-tag located N-terminal. The enzymes were purified according to 
the protocol (Sigma-Aldrich and QIAGEN) and several described methods for enzyme 
assay were used for proving activity of NysDIII (2, 99). The absorption due to the enolate 
anion of GDP-4-keto-6-deoxy-D-mannose was measured over time in samples containing 
purified enzymes.  In the assays, purified proteins with both Flag- and His-tag were used. 
The GDP-mannose 4,6-dehydratase activity could be measured spectroscopic in all assays 
with all purified proteins. The activity of the His-tag expressed enzymes was measured to 
be up to 0.18 ΔA·min-1·μg-1 protein, for the Flag-tag expressed enzymes up to 0.005 
ΔA·min-1·μg-1 protein. HPLC analysis was performed whereby the conversion of GDP-D-
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mannose to GDP-4-keto-6-deoxy-D-mannose by NysDIII expressed with C-terminal Flag-
tag, was confirmed (Figure 1).  
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Figure 1: HPLC results confirming the activity of NysDIII converting GDP-mannose to 
GDP-4-keto-6-deoxy-D-mannose. Top panel shows the substrate GDP-mannose, and the 
bottom panel show reduction of GDP-mannose which is converted to GDP-4-keto-6-deoxy-
D-mannose by addition of NysDIII. 
 
 
3.2.4 Recombinant NysDII protein 
To further confirm the proposed aminotransferase function of NysDII, this protein was also 
expressed in the same way as NysDIII with both Flag- and His-tag. NysDII was as NysDIII 
successfully expressed with Flag-tag His-tag located N-terminally. NysDII was used in a 
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coupled enzyme assay (99) together with NysDIII (as NysDII perform its function after 
NysDIII). The activity of NysDII in a coupled reaction with NysDIII could not be detected 
by HPLC analysis of any of the Flag- or His-tag expressed NysDII proteins which may be 
explained by suboptimal assay conditions, or possibly requirement of an enzyme for 
isomerization of GDP-4-keto-6-deoxy-D-mannose to GDP-3-keto-6-deoxy-D-mannose. 
Although it was postulated that isomerization might occur spontaneously (2), experimental 
verification of this hypothesis with respect to GDP-4-keto-6-deoxy-D-mannose is still 
lacking. 
 
 
3.3 MODIFICATION OF THE NYSTATIN MACROLACTONE RING AT C16 
(PAPER 3) 
 
Biosynthesis of polyene macrolide antibiotic nystatin by Streptomyces noursei involves 
oxidation of the C16 exocyclic methyl group on the macrolactone ring, leading to formation 
of a carboxyl group.  Previously, it has been suggested that a cytochrome P450 
monooxygenase encoded by the nysN gene is responsible for this modification (24). 
However, the experimental evidence of the biological function of nysN has so far been 
lacking. To study the function of nysN, this gene was inactivated by deletion and site-
directed mutagenesis resulting in production of 16-decarbox-16-methylnystatin, confirming 
the proposed function of NysN as C16 methyl oxidase. The antifungal activity of 16-
decarbox-16-methynystatin was shown to be similar to that of nystatin, while its hemolytic 
activity was considerably lower.  
 
3.3.1 Inactivation of nysN 
To study the function of nysN, this gene was inactivated by deletion through double 
homologous recombination in the previously constructed non-nystatin producing strain S. 
noursei NDA59 which can be complemented with nysA to restore nystatin production (22) . 
The resulting deletion mutant, NDDN, was shown to produce 16-decarbox-16-
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methylnystatin as expected, but at low levels. 16-decarbox-16-methylnystatin was produced 
at 1-2 % relative to nystatin production in wild type, whereby the 16-decarbox-16-
methylnystatin comprises 80-90 % of the total polyene production and nystatin 10-20 %.  
 
As the production level of 16-decarbox-16-methylnystatin level was low, it was speculated 
that less severe mutations could contribute to higher yields so that purification of 16-
decarbox-16-methylnystatin could be simplified. Two different point mutations were 
introduced into NysN. Details on the construction of the site-specific mutants can not be 
revealed due to the process of patenting. Subsequently, the mutations were introduced into 
S. noursei by means of double homologous recombination. Both resulting mutants, named 
NDDN1 and NDDN2, were shown to produce 16-decarbox-16-methylnystatin, but 
unfortunately at low levels as well; 1-2 % of nystatin production in wild type, whereby the 
16-decarbox-16-methylnystatin comprise 80-90 % of the total polyene production and 
nystatin 10-20 %. To explain the very low production levels in the nysN inactivation 
mutants, it is suggested that accumulation of decarboxylated polyene macrolides inhibits 
their biosynthetic pathway. 
 
 
3.3.2 Recombinant NysN protein 
To further confirm the function of nysN, the NysN protein was heterologously expressed 
and purified with His-tag expression system. Despite low level of 16-decarbox-16-
methylnystatin production, a few milligrams of this compound were purified and used as a 
substrate in an enzyme assay as described by Volokhan et al. (159). But unfortunately, the 
biological function of NysN as a C16-methyl oxidase could not be measured in such an 
assay. This may be explained with suboptimal assay conditions and that 16-decarbox-16-
methylnystatin might not be a true substrate for NysN. 
 
 
 
 46
3.3.3 Measurement of antifungal and hemolytic activity of nystatinolides 
In order to confirm the importance of mycosamine for antifungal activity of nystatin, MIC50 
values were measured for 16-decarbox-16-methylnystatin produced by S. noursei NDDN. 
As test organism Candida albicans ATCC 10231 was used. The MIC50 value for 16-
decarboxy-16-methylnystatin was measured to be 2.1 (± 0.2) μg/ml / 1.6 (± 0.2) μg/ml, and 
the MIC50 value for nystatin was 1.5 μg/ml in the same experiment. These results 
demonstrate that 16-decarboxy-16-methylnystatin have a similar antifungal activity as 
nystatin and suggest that the C-16 carboxyl does not significantly affect this activity. 
In order to test the in vitro toxicity of 16-decarboxy-16-methylnystatin, we carried out 
determinations of the hemolytic activity (Materials and Methods) in comparison with 
nystatin. The results of these experiments showed that 16-decarboxy-16-methylnystatin had 
significant reduced hemolytic activity compared to the parental molecule nystatin under the 
conditions tested. 
 
 
3.4 BIOCONVERSION AS A MEANS TO MODIFY NYSTATIN AGLYCONE 
(unpublished results)  
 
3.4.1 Bioconversion of nystatinolide with strains from Trondheimsfjord  
In the work aimed at generation of novel nystatin analogues, nystatinolide, produced by S. 
noursei NDD1 (Paper 2) can be an excellent target for modification by attaching other 
sugar molecules by heterologous glycosyltransferases. By feeding of nystatinolide to 
bacteria strains harboring glycosyltransferases, new compounds might be produced if the 
glycosyltransferases manage to glycosylate the aglycone with sugars other than 
mycosamine.  
 
3.4.2 Material and methods 
A sub-library of 35 different strains isolated from the Trondheim fjord (TF) sediments was 
selected for this work. This sub-library contained 29 streptomycetes demonstrating 
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antibacterial activity (proof of secondary metabolite production) and six strains that have 
been found to produce unknown polyene compounds, probably displaying antifungal 
activity. From some of these strains it was possible to amplify parts of genes presumably 
encoding glycosyltransferases by PCR. Primers were designed by A. Luzhetskyy at Prof. 
A. Bechtholds lab in Freiburg (95). The primers contain both a consensus and a 
degenerated region to efficiently detect GT genes involved in the polyketide biosynthesis in 
different Actinomycetes strains. PCR was performed with GC Rich PCR system (Roche) 
and oligonucleotides delivered by MWG Biotech (Germany). Putative glycosyltransferase 
gene fragments were successfully amplified from 14 strains in the sub-library. 
 
Conditions selected for bioconversion experiment was based on three methods (18, 113, 
142), using two different media; MP5 (25 g/l glycerol, 3 g/l yeast extract, 0.2 g/l K2HPO4, 
0.2 g/l MgSO4, 0.02 g/l FeSO4, deionised water, pH 7.2) (141) and SFM(tg) (20 g/l 
mannitol, 20 g/l soya flour, 0.20 g/l clerol, 3.40 g/l yeast powder, tap water). As control 
strains S. noursei wild type, the previously constructed non-nystatin producing strain S. 
noursei NDA59 (22) and NDD1 (Paper 2) were used. Pre cultures of the strains were grown 
in 30 ml MP5 and SFM media in 250 ml baffled flasks, 20-30oC, in Infors shaking 
incubator at 225 rpm. 50 μl pre cultures were used to inoculate 500 μl medium in deep-well 
microtiter plates. Plates were incubated at 20-30oC, 800 rpm (and relative humidity at 800 
%) in Infors incubator. Nystatinolides were added (300 μg/ml) 24 h after inoculation. The 
nystatinolide extract used in this experiment was a mix of nystatinolide and 10-deoxy 
nystatinolide purified from S. noursei NDD1 (Paper 2). There were grown two parallels of 
the strains, one where the strains were added nystatinolide and the other one not (control). 
There were taken out samples of 100 μl every 24th h after adding nystatinolides, also for the 
corresponding sample without nystatinolides. Polyenes were extracted by adding 500 μl 
DMSO to 100 μl sample, shaking for 30 min at RT and centrifuging at 13000 rpm for 5 
min. Extracts were then directly analyzed by LC-MS-TOF. UV data was inspected 
manually to find eventually new tetraene characteristic absorption spectra. MS data were 
compared for each strain, with and without nystatinolides added. 
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 3.4.3 Results 
Significant MS-signals that could be correlated with unique tetraenes was only observed 
from strain MP21-11 grown in SFM media (Figure 2). Those two tetraenes were found to 
have m/z at 781.4395 (retention time 12.1) and 797.4307 (retention time 11.3) resulting in 
the stochiometric formulas C41H66O14 and C41H66O15. These formulas corresponded to 
addition of water to 10-deoxy nystatinolide and nystatinolide respectively. Further it was 
observed that tetraene UV spectra correlating with m/z 781 and 797 have shifted 0.5-1 nm 
compared to those of the added nystatinolides. Based on these results, a hypothesis would 
be that a water molecule is added (which means +18 Da as one H atom and one -OH group 
of each C atom) to one of the double bindings in the diene-region in 10-deoxy nystatinolide 
and nystatinolide. We can not exclude a possibility that addition of nystatinolides triggered 
production of new polyenes by the strain MP21-11. Further work will be required in order 
to analyze these results in detail. 
 
 49
797.4307
781.4395
 
Figure 2: Strain MP21-11 without feeding of nystatinolides  (top panel) and with feeding 
of nystatinolides (bottom panel). Exact mass m/z (M-H– ion) of putative new nystatin 
analogues are shown by black arrows; unmodified remaining nystatinolides are shown by 
white arrows.   
 
 
For strain EC(S)-29-A grown in MP5 media there were observed traces of a unique tetraene 
at retention time 11.0 min (Figure 3). The UV-signal for this compound was very weak, and 
correlates with three observed masses in time; 922.5581 Da, 919.5668 Da and 883.5872 Da 
where the two latter masses constitutes 90 % of MS-counts. Possible stochiometric 
formulas for the 919 compound would be estimated to be C47H83N2O13Cl (0.09 ppm error 
and good isotope distribution), C50H80NO14 (0.7 ppm error and not so good isotope 
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distribution), C44H85NO16Cl (3.0 ppm error and good isotope distribution) or C47H82O17 
(3.5 ppm error and not so good isotope distribution). Based on these results it is most 
reliable that the compound contains a Cl-atom.  
Possible stochiometric formulas for the 883 compound were suggested as C44H84NO16 (0.6 
ppm error and good isotope distribution) or C47H82N2O13 (2.4 ppm error and good isotope 
distribution). These two formulas correlate well with the loss of H and Cl atoms from the 
two chlorinated compounds as mentioned above, and it is not unlikely that such loss can be 
due to ionization. 
 
Both strain MP21-11 and EC(S)-29-A, with and without added tetraene-substrate, were 
shown to produce heptaene compounds, in trace amounts not sufficient for reliable 
determination of their molecular masses or purification and testing. Next we tried to use the 
two identified bioconverting strains for modification of nystatin and amphotericin utilizing 
same procedures as for nystatinolides. However, modifications similar to those observed 
for nystatinolide and 10-deoxy nystatinolide could not be identified on these substrates, and 
other modified derivates were not identified. These results indicate that the strains could not 
use nystatin and amphotericin as substrates for modifications in the same way as 
nystatinolide and 10-deoxy nystatinolide. 
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 919.5668
Figure 3: Strain EC(S)-29-A without nystatinolides feeding (top panel), and EC(S)-29-A 
with feeding of nystatinolides  (bottom panel). Exact mass m/z (M-H– ion) of putative 
new nystatin analogue is shown by black arrow; unmodified remaining nystatinolides are 
shown by white arrows. 
 
 
Characterization of nystatinolide modifying strains by 16s rDNA sequencing 
The 16s rDNA from the nystatinolide modifying strains MP21-11 and EC(S)-29-A was 
amplified by PCR and sequenced. PCR was performed by using Expand High Fidelity PCR 
System (Roche) (4 min at 94°C followed by 35 cycles of 45 s at 94°C, 20 s at 55°C and 2 
min at 66°C followed by a 5 min extension step at 70°C), and primers from MWG Biotech 
AG (F27: 5’-AGAGTTTGATCMTGGCTCAG-3’ and R1492: 5’-
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TACGGYTACCTTGTTACGACTT-3’). The amplified fragments were cloned into a 
pDrive vector (Qiagen PCR Cloning Kit), sequencing was performed by MWG Biotech AG 
and sequence alignment was performed by BLAST search. Strain MP21-11 showed 99 % 
sequence identified to Streptomyces sp. VTT E-99-1330 (A83) (149) and strain EC(S)-29-A 
showed 99 % sequence identified to Streptomyces sp. VTT E-99-1336 (B329) (149). Both 
latter streptomycetes have been isolated from water-damaged buildings. 
 
3.4.4 Bioconversion of nystatinolide with Saccharothrix espanaensis 
Nystatinolide was also fed to a Saccharothrix espanaensis that previously has been shown 
to glycosylate different natural compounds with the deoxysugar rahmnose (Prof A. 
Bechthold, unpublished data). This work was performed by A. Linnenbrink at Prof A. 
Bechtholds lab in Freiburg (Germany). But unfortunately no new nystatin/nystatinolide 
derivates could be observed. 
 
For the main culture a single baffled 300 ml flask containing 100 ml of NL111 medium (20 
g of Lab Lemco meat extract, 100 g of malt extract, 10 g of CaCO3 ad 1000 ml tap water, 
pH 7.2) and 200µl of DMSO with 5 mg of nystatinolide was inoculated with 2 ml of a 24 h 
preculture in TSB medium (30 g of BactoTM Tryptic Soy Broth ad 1000 ml tap water, pH 
7.2). The main culture was incubated for 8 days on a rotary shaker at 28°C and 180 rpm. 
For extraction the culture was centrifuged to separate the cell pellet from the supernatant.  
 
LC / MS method: 
The analysis was carried out on an Agilent 1100 system (Agilent Technologies, 
Waldbronn) equipped with a diode array (DAD, G1315B) and a quadrupole mass detector 
(MSD, G1946D). For nystatinolide electrospray ionization was used. 
Column: Zorbax SB-C18 (150 x 4.6 mm; 5 µm), column flow: 0.7 ml/min. 
Solvent A: acetonitrile; solvent B: water with 0.5 % acetic acid. 
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3.5 ATTEMPTS ON ALTERNATIVE GLYCOSYLATION OF NYSTATINOLIDE 
USING GT HYBRIDS AND DEOXYSUGAR BIOSYNTHESIS GENE CASSETTES 
(unpublished results) 
 
3.5.1 Construction of hybrids between the glycosyltransferase genes nysDI, urdGT2 
and lipGTF 
In this work we designed hybrid glycosyltransferases, in the means that these hybrids could 
glycosylate the nystatinolide. Such hybrids could theoretically attach sugar molecules other 
than mycosamine, complement the function of nysDI, or attach the sugar moiety in another 
position. For construction of hybrid glycosyltransferases, two heterologous 
glycosyltransferase genes were used in combination with nysDI: urdGT2 from 
Streptomyces fradiae Tü2717 (69), and lipGTF from Streptomyces aureofaciens (Tü117) 
(15). These genes were selected on the basis of chemical structure of the compounds 
glycosylated by the corresponding GTs, which showed some similarity to the nystatin 
aglycone. In addition, the UrdGT2 enzyme has previously been shown to have relaxed 
substrate specificity (69).  
 
Streptomyces fradiae Tü2717 is the producer of urdamycin A (Figure 4), an antibacterial 
antibiotic and anticancer agent (48). Urdamycin A molecule consists of an angucyclic 
polyketide core and four deoxyhexose moieties: two D-olivoses (first and last sugar of a C-
glycosidically bound trisaccharide chain at the C9 position) and two L-rhodinoses (in the 
middle of the trisaccharide chain and at the C12b position). Two GTs are involved in the C-
glycosyl transfer of D-olivose at C9 (UrdGT2) and in conversion of aquayamycin to 
urdamycin G (UrdGT1c). It has been demonstrated that these two glycosyltransferases 
show relaxed substrate specificity for their activated deoxysugar co-substrate and their 
alcohol substrate, respectively. Both GTs can transfer activated D-rhodinose (instead of D-
olivose) to C9, and attach L-rhodinose to the C4a normally occupied by a D-olivose unit 
(69). 
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Figure 4: Chemical structure of Urdamycin A 
 
Streptomyces aureofaciens Tü117 is the producer of α-lipomycin (Figure 5) (88). α-
lipomycin is an acyclic polyene antibiotic where a carbonyl group links a pentaene chain 
with a derivate of N-methyl-tetramic acid, composing the aglycone. An L-digitoxose 
moiety is attached to the polyketide part of the aglycone presumably by the 
glycosyltransferase LipGTF. α-lipomycin is active against Gram-positive bacteria but has 
no effect on the growth of fungi and gram-negative bacteria (15). 
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Figure 5: Chemical structure of α-Lipomycin 
  
Since the mycosamine biosynthetic pathway is intact in the S. noursei NDD1 mutant; we 
have decided to introduce our hybrids in this strain. This would allow, besides possible 
generation of novel glycosylated nystatin analogues, to assess specificity of the 
glycosyltransferase hybrids. With this in mind, hybrids of the glycosyltransferase nysDI 
and urdGT2, and nysDI and lipGTF, were constructed by PCR Overlap Extension or “Gene 
SOEing” method. By Gene SOEing two DNA fragments can easily be combined by 
overlap extension leading to production of chimeric genes. By using pair of primers with 
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complementary regions, overlapping strands of PCR amplified DNA fragments from 
various sources can be spliced together by the extension of overlapping strands in a 
subsequent reaction (155).  
As the glycosyltransferases contain two domains connected by a linker region (123), four 
hybrid combinations were constructed between each of nysDI/urdGT2 and nysDI/lipGTF 
pairs (Table 1 and 2). As NysDI, UrdGT2 and LipGTF are inverting GT-B fold 
glycosyltransferases, the N-terminal domain provides the acceptor binding site, and the C-
terminal domain provides the donor binding site (123). The linker region in nysDI, urdGT2 
and lipGTF was predicted based on sequence alignment (Clustal W) in comparison with the 
glycosyltransferase GtfB, for which a crystal structure is available (108).  
 
Table 1. Overview of combinations for hybrids between NysDI and UrdGT2. 
 N-terminal Linker region C-terminal 
Hybrid 1: A1+D1 A1: nysDI nysDI D1: urdGT2 
Hybrid 2: A2+D2 A2: nysDI D2: urdGT2 urdGT2 
Hybrid 3: C1+B1 C1: urdGT2 urdGT2 B1: nysDI 
Hybrid 4: C2+B2 C2: urdGT2 B2: nysDI nysDI 
 
 
Table 2. Overview of combinations for hybrids between NysDI and LipGTF. 
 N-terminal Linker region C-terminal 
Hybrid 1: A1+D1 A1: nysDI nysDI D1: lipGTF 
Hybrid 2: A2+D2 A2: nysDI D2: lipGTF lipGTF 
Hybrid 3: C1+B1 C1: lipGTF lipGTF B1: nysDI 
Hybrid 4: C2+B2 C2: lipGTF B2: nysDI nysDI 
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Figure 6: GeneSOEing PCR; A/B represents one gene separated by a linker region, and 
C/D represents another gene separated with a linker region. A and C represent N-terminal 
part of the genes, and B and D represent C-terminal parts of the genes. The primers A.Rew, 
and B.Rew, C.Rew and D.rew are megaprimers (ca 50 nucleotides) containing tails (ca 25 
nucleotides) homologous to the gene fragment that the first amplified fragment shall be 
fused with. 
 
PCR amplification, sequencing and DNA manipulations 
Oligonucleotide primers were purchased from MWG Biotech AG. The PCR’s were 
performed with the GC Rich PCR System (Roche Molecular Biochemicals) using the 
Eppendorf Mastercycler (Eppendorf, Germany), as described previously (23). General 
DNA manipulations were performed as described previously (138). DNA fragments from 
agarose gels were purified using Qiaex II kit (Qiagen, Germany). DNA sequencing was 
performed by MWG Biotech AG. 
 
Construction of hybrid vectors 
The ca 1.5 kb PCR amplified hybrids of NysDI/UrdGT2 and NysDI/LipGTF were digested 
with SphI/HindIII or NotI/HindIII and subcloned via pGEM11Zf + (Promega) before they 
were joined together with the 0.2 kb EcoRI/SphI fragment of pGEM7ZfErm*li (C.R. 
Hutchinson) into the integrative vector pSOK804 (141).  
 
A                        B C                        D
A.Fwd B.Fwd
A.Rew B.Rew
C.Fwd D.Fwd
D.RewC.Rew
A +  B C + D
st PCRFir
A                        D C                        B
A.Fwd
B.RewD.Rew
C.Fwd
Hybrid: A/D Hybrid: B
Second PCR
C/
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Analysis  
To analyze polyene macrolide production, NDD1 mutant harboring the hybrids (ten 
parallels of each strain) were incubated for 5 days in a defined production medium, and 
culture extracts were analyzed for the presence of nystatin-related polyene macrolides using 
LC-MS-TOF. Neither novel nystatin analogues nor restoration of nystatin biosynthesis 
were observed in the extracts.   
 
Mutations were identified in some of the hybrids by sequencing but most of the mutations 
were silent and none of them introduced stop codons. Based on this we still decided to test 
the hybrids if they had any function or at least any complementing function. This might be 
the explanation why some hybrids didn’t work, even if a mutation does not lead to amino 
acid change the structure and function might still be altered influencing the activity of the 
enzyme. Of other reasons why the hybrids didn’t work can for instance be that the overall 
structure of the GT hybrids could have been significantly disturbed, rendering them non-
functional. The active site might be interrupted as well, as the linker region was predicted, 
and experimental data confirming these regions are lacking for the used GTs. 
 
 
3.5.2 Introduction of L-rhamnose biosynthesis genes into S. noursei 
 
Elloramycin (Figure 7) is an anthracycline drug structurally related to tetracenomycin C 
and containing a methylated L-rhamnose moiety at the C8 (132).  
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Figure 7: Chemical structure of elloramycin. 
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L-rhamnose biosynthesis genes from S. olivaceus Tü2353 have been cloned and analysed, 
and successfully used for construction of gene cassettes useful for combinatorial 
biosynthesis. A construct containing L-rhamnose biosynthesis genes, named pRHAM 
(132), was received from Prof. J.A Salas group (University of Oviedo, Spain). pRHAM 
contains four genes encoding the enzymatic functions necessary for the biosynthesis of 
dTDP-L-rhamnose; oleL, oleS, oleE and oleU, in a single transcriptional unit under the 
control of the ermE*p promoter from Saccharopolyspora erythrea (ermEp) (132). All the 
genes plus the promoter were isolated as a HindIII/EcoRI fragment and directly cloned into 
pSOK804 (141). The resulting plasmid was introduced into both S. noursei nysDI and 
nysDII deficient mutants (NDD1 and NDD2) (Paper 2). 
To analyze polyene macrolide production of NDD2 and NDD1 mutants harboring the L-
rhamnose biosynthetic genes, ten parallels of each strain were incubated for 5 days in a 
defined production medium, and culture extracts were analyzed for the presence of 
nystatin-related polyene macrolides using LC-MS-TOF. No new nystatin analogues were 
detected in the extracts, suggesting that NysDI might have a strong preference for GDP-
mycosamine as a donor substrate and can not attach L-rhamnose to the nystatin aglycone.  
The latter notion is supported by the fact that in previous experiments, as for the nysDII 
inactivation mutant (Paper 2), where a deaminated deoxysugar was expected to be attached 
to the nystatin aglycone, a nystatinolide was produced instead. 
 
 
3.5.3 Introduction of the N-methyltransferase OleM1 from Streptomyces antibioticus  
S. antibioticus is the producer of a 14-unit macrolide oleandomycin (Figure 8). The 
oleandomycin molecule is composed of a macrolactone ring (oleandolide) with two 6-
deoxysugars (L-oleandrose and D-desosamine) attached. The methyltransferase OleM1 is 
proposed to encode a N-methyltransferase responsible for dimethylation of the amino group 
at C-3 in D-desosamine (115). In an attempt to afford modification of the mycosamine 
moiety of nystatin, more specifically, methylation of the amino group, the gene for N-
methyltransferase oleM1 from the S. antibioticus was introduced to S. noursei wild type.  
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 The oleM1 was amplified by PCR with oligonucleotides purchased from MWG Biotech 
AG, encompassing endonuclease sites NotI and HindIII. As a template, cosAB24 
(containing part of the oleandomycin gene cluster; oleM1 740 bp, derivate of PKC505 
(128)) received from Prof. J.A. Salas group (University of Oviedo, Spain) was used. The 
PCR product was digested with NotI/HindIII, and cloned via pGEM11 in NotI/HindIII sites 
and further joined together with the 0.2 kb EcoRI/SphI fragment of pGEM7ZfErm*li (C.R. 
Hutchinson), into the integrative vector pSOK804 (141). The resulting construct was 
introduced into S. noursei wild type. 
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Figure 8: Chemical structure of Oleandomycin 
 
To analyze polyene macrolide production of S. noursei harboring the construct with 
OleM1, ten parallel strains were incubated for 5 days in a defined production medium, and 
culture extracts were analyzed for the presence of nystatin-related polyene macrolides using 
LC-MS-TOF. No new nystatin analogues could be detected in the extracts of the 
recombinant strains. This might be explained by the fact that mycosamine is activated with 
GDP, while desosamine is activated with TDP. Presumably, OleM1 can not accept GDP-
sugar as substrate, or at least not GDP-mycosamine. It might also be that the nystatin 
glycosyltransferase, nysDI, does not accept N-methylated mycosamine as a substrate. 
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4 CONCLUDING REMARKS AND FURTHER PERSPECTIVES 
 
The work in this thesis has given us a better knowledge of the post PKS modifying genes in 
the nystatin biosynthesis cluster in S. noursei. 
 
The functions of genes involved in mycosamine biosynthesis (nysDIII and nysDII) and 
attachment (nysDI) of the antifungal polyene macrolide nystatin produced by S. noursei 
were studied and confirmed. By recombinant expression of NysDIII in E. coli, the GDP-D-
mannose 4,6-dehydratase activity was demonstrated in vitro. NysDII was recombinant 
expressed as well, but unfortunately the activity could not be demonstrated which can be 
explained with the absence of an isomerase suggested to be required for isomerisation of 
GDP-4-keto-6-deoxy-D-mannose to GDP-3-keto-6-deoxy-D-mannose. But importantly, 
soluble recombinant proteins involved in mycosamine biosynthesis are expressed which 
can be used in future for in vitro synthesis of aminosugars.  
 
Inactivation of nysDII and nysDI by in-frame deletion of the genes individually from the 
chromosome led to main production of nystatinolide and 10-deoxynystatinolide. Although 
the production level in ΔNysDII was surprisingly low compared to ΔNysDI, the nystatin 
biosynthesis was partially restored by introduction of both the nysDII and nysDI genes in-
trans into the respective two mutant strains. A clearly conversion of nystatinolides to 
nystatin was observed for both mutants confirming the predicted roles of the two genes in 
mycosamine biosynthesis and attachment. The presumed importance of mycosamine for the 
biological activity of nystatin was studied as well. Both the antifungal as well as the 
hemolytic activity of the purified nystatinolide molecules were strongly reduced compared 
to nystatin confirming the importance of mycosamine for the nystatin activity.  
 
To study and confirm the biological function of the post PKS modifying P450 
monooxygenase nysN the gene was deleted resulting in production of 16-decarboxy-16-
methylnystatin. Unfortunately the production of 16-decarboxy-16-methylnystatin was low 
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and two less severe mutations in NysN was introduced in an attempt to receive a nysN 
inactivated mutant producing higher levels of 16-decarboxy-16-methylnystatin. Both site 
specific mutants produced 16-decarboxy-16-methylnystatin, but unfortunately not leading 
to higher amounts then the deletion mutant. 16-decarboxy-16-methylnystatin was purified 
from the deletion mutant and its antifungal activity was measured to be the same as for 
nystatin, whereas the toxicity was measured to be lower. 
For amphotericin it is demonstrated a reduction in toxicity by suppression of the charge of 
the exocyclic group and for rimocidin an amidotransferase activity involved in chemical 
modifications of the free carboxyl group of two typical polyene macrolide polyenes into an 
amide group leads to improved pharmaceuticals. It would be very interesting to perform 
modifications of the C16-carboxy group to reduce the toxicity. And as inactivation mutant 
of nysN producing 16-decarboxy-16-methylnystatin is available, there are many 
possibilities for further modifications although the challenge will be the low production 
levels. 
 
Concerning bioconversion as a means to modify nystatin aglycone, we unfortunately could 
not find a strain that could glycosylate nystatinolide though some harbored GTs. On the 
other hand two strains successfully modified nystatinolide in an interesting way, though the 
production levels of those derivates were low and nystatinolide derivates are inactive. In a 
further perspective, bioconversion and growth conditions could be optimized to increase the 
levels of modified nystatinolide derivates, purify these compounds and feed them to e.g. the 
non nystatin producing strain S. noursei NDA59 with intact NysDI to eventually 
glycosylate these compounds.  
 
The work with developing new novel nystatin derivates by use of hybrid GTs, introducing 
other deoxysugar cassettes, methylation of mycosamine was unfortunately not successful. 
The nystatin glycosyltransferase NysDI seem to be highly specific in binding and 
attachment. This is a difficult and challenging project but which can led to very interesting 
results if it is successful. There are still many possibilities for modifying the nystatin and 
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nystatinolide derivate, e.g. by trying to attach olivose. The constructed hybrids between 
NysDI and UrdGT2 can also be tested in S. fradiae for modification of urdamycin as the 
UrdGT2 inactivation mutant is available, and UrdGT2 previously have shown some 
substrate specificity. 
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